Wednesday, July 8, 2026

Drug profile · INN

abacavir

abacavir (ZIAGEN) is an FDA-listed pharmaceutical active ingredient. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Antiinfectives for systemic use (J05) J05AR13
US status approved
Patents linked 11
Pipeline programs 32
News articles 0
Drug details — abacavir
US status
approved
Class
Antiinfectives for systemic use (J05)
Route
ORAL
Patents
11
Programs
32
Data quality
0.84

Quick answer

abacavir (ZIAGEN) is an FDA-listed pharmaceutical active ingredient. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN abacavir
Brand ZIAGEN
Therapeutic class Antiinfectives for systemic use (J05)
Route ORAL
Formulation TABLET, FOR SUSPENSION
ATC code J05AR13

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved

Pipeline programs

  1. ARGX-117-2302 Phase 3 · Argenx · Multifocal Motor Neuropathy
  2. ARGX-117-2401 Phase 3 · Argenx · Chronic inflammatory demyelinating polyneuropathy (CIDP)
  3. Bedaquiline (B) Phase 3 · First People's Hospital · Pulmonary Tuberculosis
  4. D3 (Penta 21) Phase 3 · Telethon Foundation · HIV-infected
  5. Dolutegravir/abacavir/lamivudine FDC Phase 3 · ViiV Healthcare · Infection, Human Immunodeficiency Virus
  6. GS-US-563-5926 Phase 3 · Gilead Sciences · HIV-1 Infection
  7. Sarilumab Phase 3 · Regeneron UK · RA
  8. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion Phase 2 · Alnylam Netherlands · TTR-mediated Amyloidosis

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)
  1. WO 2025233501

    CONJUGUÉS COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I

    Expires Wed Nov 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. CA 3266054

    COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE

    Expires Wed Mar 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. CA 3235096

    METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE

    Expires Wed May 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. CA 3207179

    METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE

    Expires Wed Jul 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. WO 2019048531

    NANOPARTICULES MODIFIÉES PAR L'ALBUMINE PORTANT UN LIGAND DE CIBLAGE

    Expires Wed Mar 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. WO 2019016112

    COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P

    Expires Wed Jan 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. WO 2018175449

    COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE

    Expires Wed Sep 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. WO 2018083171

    COMPOSÉS SPIRO EN TANT QUE MODULATEURS DE S1P

    Expires Thu May 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 2017349653

    METHODS FOR TREATING SPINAL CORD INJURY AND PAIN

    Expires Wed Dec 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 2017260158

    QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR

    Expires Wed Sep 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 2017174672

    FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS

    Expires Wed Jun 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is abacavir?

abacavir (ZIAGEN) is an FDA-listed pharmaceutical active ingredient. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for abacavir?

ZIAGEN is a marketed brand name for abacavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of abacavir?

abacavir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.